Description: Brainsway is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which Brainsway received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 (for MDD) and in August 2018 (for OCD). Brainsway is currently conducting clinical trials of Deep TMS in other psychiatric, neurological and addiction disorders, including smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis (MS) and post-stroke rehabilitation.
Home Page: www.brainsway.com
BWAY Technical Analysis
Bynet Building
Jerusalem,
9777518
Israel
Phone:
972 2 582 4030
Officers
Name | Title |
---|---|
Dr. Christopher R. von Jako Ph.D. | Pres & CEO |
Mr. Richard Scott Areglado | Sr. VP & CFO |
Mr. Hadar Levy | Sr. VP & COO |
Mr. Christopher J. Boyer Ph.D. | VP of Global Marketing |
Mr. Avner Hagai | Founder & Independent Vice-Chairman |
Prof. Abraham Zangen | Co-Founder, Member of Scientific Advisory Board & Director |
Dr. Yiftach Roth Ph.D. | Chief Scientist |
Mr. Menachem C. Klein Esq. | VP, Gen. Counsel & Corp. Sec. |
Dr. Aron Tendler | Chief Medical Officer |
Ms. Moria Ankri | VP R&D |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Health Care Equipment & Services |
GIC Industry: | Health Care Equipment & Supplies |
GIC Sub-Industry: | Internet Software & Services (discontinued effective close of September 28, 2018) |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.6391 |
Price-to-Sales TTM: | 1.1136 |
IPO Date: | 1999-10-06 |
Fiscal Year End: | December |
Full Time Employees: | 118 |